Lymph Node Staging with a Combined Protocol of F-FDG PET/MRI and Sentinel Node SPECT/CT: A Prospective Study in Patients with FIGO I/II Cervical Carcinoma.
Matthias Weissinger, Florin-Andrei Taran, Sergios Gatidis, Stefan Kommoss, Konstantin Nikolaou, Samine Sahbai, Christian la Foug��re, Sara Yvonne Brucker, Helmut Dittmann
Author Information
Matthias Weissinger: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany.
Florin-Andrei Taran: Department of Women's Health, University Hospital Zurich, Zurich, Switzerland.
Sergios Gatidis: Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Tuebingen, Germany.
Stefan Kommoss: Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany.
Konstantin Nikolaou: Department of Diagnostic and Interventional Radiology, University Hospital Tuebingen, Tuebingen, Germany.
Samine Sahbai: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany.
Christian la Foug��re: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany; christian.lafougere@med.uni-tuebingen.de.
Sara Yvonne Brucker: Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany; christian.lafougere@med.uni-tuebingen.de.
Helmut Dittmann: Department of Nuclear Medicine and Clinical Molecular Imaging, University Hospital Tuebingen, Tuebingen, Germany; christian.lafougere@med.uni-tuebingen.de.
Lymph node metastasis (LNM) is present in a minority of patients with early stages of cervical carcinomas. As conventional imaging including PET/CT has shown limited sensitivity, systematic lymphadenectomies are often conducted for staging purposes. Therefore, the aim of this prospective study was to analyze the impact of F-FDG PET/MRI in addition to sentinel lymph node (SLN) biopsy on lymph node (LN) status. Forty-two women with an initial diagnosis of F��d��ration Internationale de Gyn��cologie et d'Obst��trique (FIGO) IA-IIBcervical carcinoma were included between March 2016 and April 2019. Each patient underwent preoperative whole-body F-FDG PET/MRI and SLN imaging with SPECT/CT after intracervical injection of Tc-labeled nanocolloid. Systematic lymphadenectomy and SLN biopsy served as the reference standard. Staging using PET/MRI was performed by nuclear medicine and radiology experts working in consensus. One patient was excluded from surgical staging because of liver metastases newly diagnosed on PET/MRI. The overall prevalence of LNM in the remaining 41 patients was 29.3% (12/41). Five of 12 patients with LNM had solely small metastases with a maximum diameter of 5 mm. The consensus interpretation showed PET/MRI to have a specificity of 100% (29/29; 95% CI, 88.3%-100%) for LNM staging but a low sensitivity, 33.3% (4/12; 95% CI, 12.8%-60.9%). LN size was the most important factor for the detectability of metastases, since only LNMs larger than 5 mm could be identified by PET/MRI (sensitivity, 57.1% for >5 mm and 0% for ���5 mm). Paraaortic LNM was evaluated accurately in 3 of the 4 patients with paraaortic LN metastasis. SLNs were detectable by SPECT/CT in 82.9% of the patients or 69.0% of the hemipelves. In cases with an undetectable SLN on SPECT/CT, the malignancy rate was considerably higher (31.2% vs. 19.3%). The combination of PET/MRI and SLN SPECT/CT improved the detection of pelvic LNM from 33.3% to 75%. F-FDG PET/MRI is a highly specific N-staging method and improves LNM detection. Because of the limited sensitivity in frequently occurring small LNMs, PET/MRI should be combined with SLN mapping. The proposed combined protocol helps to decide whether extensive surgical staging is necessary in patients with FIGO I/II cervical cancer.
